Attention INSP investors: Your trust may have been betrayed. The Schall Law Firm, a renowned advocate for shareholder rights, is leading a class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP), alleging the company misled investors in violation of federal securities laws. But here's where it gets controversial: while Inspire publicly boasted about its readiness and market demand for the Inspire V launch, the reality was starkly different. The launch was a flop, with weak demand and a lack of basic preparation for clinical adoption. And this is the part most people miss: investors who purchased INSP securities between August 6, 2024, and August 4, 2025, could be entitled to compensation for their losses.
If you’re an investor who suffered losses during this period, you have until January 5, 2026, to take action. Here’s how you can get involved:
1. Click here to participate in the lawsuit and potentially recover your losses.
2. Contact Brian Schall directly at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or call 310-301-3335 for a free consultation.
3. Visit the firm’s website at www.schallfirm.com or email bschall@schallfirm.com for more information.
But here’s the catch: The class has not yet been certified, meaning you’re not represented by an attorney unless you actively join the case. If you do nothing, you remain an absent class member, potentially missing out on recovery.
According to the lawsuit, Inspire’s public statements were not just misleading—they were materially false. The company’s failure to follow basic steps for device adoption raises serious questions about its leadership and transparency. Is this a case of overpromising and underdelivering, or something more deliberate? We want to hear your thoughts.
This isn’t just about financial losses; it’s about holding companies accountable for their actions. The Schall Law Firm specializes in securities class actions and shareholder rights litigation, representing investors globally. Their expertise could be your key to justice.
Thought-provoking question: Should investors bear the brunt of a company’s missteps, or is it time for stricter accountability measures in the medical device industry? Share your opinions in the comments below.
Disclaimer: This press release may be considered Attorney Advertising in certain jurisdictions under applicable laws and ethical rules.
